SCHEMBL2178639

SCHEMBL2178639

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)c4cccnc4Cl)cc3)cc2C1=O

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
MAPT P10636 4/20 0.44
RAB9A P51151 3/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4E B2RXH2 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
GAA P10253 1/20 0.43
HTT P42858 2/20 0.43
NPC1 O15118 1/20 0.42
ATM Q13315 1/20 0.42
LMNA P02545 2/20 0.41
TP53 P04637 1/20 0.41
EGFR P00533 1/20 0.40
SDCBP O00560 1/20 0.40
SDC2 P34741 1/20 0.40
NR2E3 Q9Y5X4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13719068 1.00 ALDH1A1 (0.44) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL13719200 0.92 GAA (0.42) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL13719199 0.92 LMNA (0.44) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL2179808 0.92 LMNA (0.44) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL2177068 0.88 SMO (0.53) MAPTRAB9ANPC1LMNATP53
SCHEMBL2181361 0.88 SMO (0.53) MAPTRAB9ANPC1LMNATP53
SCHEMBL13718795 0.84 SMO (0.44) MAPTLMNATP53EGFRSDCBP
SCHEMBL2180240 0.83 SDCBP (0.48) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL13719075 0.83 SDCBP (0.48) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL2179082 0.83 LMNA (0.44) MAPTLMNATP53SDCBPSDC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT ALDH1A1 715/4885MAPT 116/4885RAB9A 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.